Abstract
Gene therapy is rapidly emerging as a viable clinical strategy to treat prostate cancer. New developments, such as targeted expression of therapeutic genes, and viruses that are designed to selectively replicate in prostate cancer cells have led to vectors with improved safety, even in elderly male patients. This review describes the various different viral and non-viral strategies employed to date, with a summary of current clinical trials. The main focus of the review is a discussion of the need, and the potential methods that can be used for targeted expression of the therapeutic gene specifically to prostate tumours and metastases. This includes methods of abrogating vector transduction of non-specific tissues, enhancement of transduction into prostate tumour tissue, transcriptional control of the therapeutic gene and some examples of prostate cancer-specific therapeutic genes. We also consider the future of prostate cancer gene therapy and the factors that should be taken into account when designing clinical trials, in a field that is expected to impact on clinical management of a common tumour type.
Keywords: prostate cancer, gene therapy, virus vectors, tissue specificity
Current Pharmaceutical Design
Title: Targeting Gene Therapy for Prostate Cancer
Volume: 10 Issue: 5
Author(s): N. J. Maitland, L. J. Stanbridge and V. Dussupt
Affiliation:
Keywords: prostate cancer, gene therapy, virus vectors, tissue specificity
Abstract: Gene therapy is rapidly emerging as a viable clinical strategy to treat prostate cancer. New developments, such as targeted expression of therapeutic genes, and viruses that are designed to selectively replicate in prostate cancer cells have led to vectors with improved safety, even in elderly male patients. This review describes the various different viral and non-viral strategies employed to date, with a summary of current clinical trials. The main focus of the review is a discussion of the need, and the potential methods that can be used for targeted expression of the therapeutic gene specifically to prostate tumours and metastases. This includes methods of abrogating vector transduction of non-specific tissues, enhancement of transduction into prostate tumour tissue, transcriptional control of the therapeutic gene and some examples of prostate cancer-specific therapeutic genes. We also consider the future of prostate cancer gene therapy and the factors that should be taken into account when designing clinical trials, in a field that is expected to impact on clinical management of a common tumour type.
Export Options
About this article
Cite this article as:
Maitland J. N., Stanbridge J. L. and Dussupt V., Targeting Gene Therapy for Prostate Cancer, Current Pharmaceutical Design 2004; 10 (5) . https://dx.doi.org/10.2174/1381612043453252
DOI https://dx.doi.org/10.2174/1381612043453252 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Prostate Carcinogenesis: Insights in Relation to Epigenetics and Inflammation
Endocrine, Metabolic & Immune Disorders - Drug Targets Deregulated Expression of miR-224 and its Target Gene: CD59 Predicts Outcome of Diffuse Large B-cell Lymphoma Patients Treated with R-CHOP
Current Cancer Drug Targets Ring Finger Ubiquitin Protein Ligases and Their Implication to the Pathogenesis of Human Diseases
Current Pharmaceutical Design Natural Compounds as Anticancer Agents Targeting DNA Topoisomerases
Current Genomics Urokinase-type Plasminogen Activator (uPA) and its Receptor (uPAR): Development of Antagonists of uPA / uPAR Interaction and their Effects In Vitro and In Vivo
Current Pharmaceutical Design Electrochemically Driven Supramolecular Interaction of Quinones and Ferrocifens: An Example of Redox Activation of Bioactive Compounds
Current Topics in Medicinal Chemistry The Chromogranin A-Derived Vasostatins: New Players in the Endocrine Heart
Current Medicinal Chemistry Multi-Component Reactions of Cyclohexan-1,3-dione: Synthesis of Fused Pyran, Pyridine, Thiophene and Pyrazole Derivatives with c-Met, Anti-Proliferative Activities
Anti-Cancer Agents in Medicinal Chemistry Impaired Expression and Function of Signaling Pathway Enzymes by Anthocyanins: Role on Cancer Prevention and Progression
Current Enzyme Inhibition Gene Expression Profile Classification: A Review
Current Bioinformatics Polymorphisms of Human N-Acetyltransferases and Cancer Risk
Current Drug Metabolism Advancements within Modern Machine Learning Methodology: Impacts and Prospects in Biomarker Discovery
Current Medicinal Chemistry Machine Learning and Perturbation Theory Machine Learning (PTML) in Medicinal Chemistry, Biotechnology, and Nanotechnology
Current Topics in Medicinal Chemistry The Immunological Side-Effects of Sedative Agents in the Intensive Care Unit
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Insights into Angiogenesis in Non-Small Cell Lung Cancer: Molecular Mechanisms, Polymorphic Genes, and Targeted Therapies
Recent Patents on Anti-Cancer Drug Discovery Peptide-Based Anticancer Vaccines: Recent Advances and Future Perspectives
Current Medicinal Chemistry Proteases as Anti-Cancer Targets - Molecular and Biological Basis for Development of Inhibitor-Like Drugs Against Cancer
Anti-Cancer Agents in Medicinal Chemistry Merkel Cell Carcinoma – Current State and the Future
Current Cancer Therapy Reviews Structural Biology Insight for the Design of Sub-type Selective Aurora Kinase Inhibitors
Current Cancer Drug Targets Melatonin and Respiratory Diseases: A Review
Current Topics in Medicinal Chemistry